Filing summary
Filing identity and period: The supplied filing is for DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI), not Tuhura Biosciences, Inc. It is a Form 10-Q for the quarter ended December 31, 2019, covering the six months ended that date. This is DelMar’s second fiscal quarter of fiscal 2020, despite the request metadata specifying “2019 Q2.”
Business context and financial position
DelMar is a clinical-stage drug developer focused on VAL-083, being studied primarily for glioblastoma (GBM). It reported no revenue to date and depends on financing or potential partnerships to fund operations.
| Metric | Period / amount |
|---|---|
| Cash and cash equivalents | $6.35 million at December 31, 2019, versus $3.72 million at June 30, 2019 |
| Working capital | $5.47 million, versus $1.96 million |
| Total assets | $6.51 million |
| Current liabilities | $1.03 million; the supplied balance sheet reports no debt |
| Stockholders’ equity | $5.48 million, versus $1.97 million |
| Operating cash used | $3.98 million for the six months, versus $3.05 million in the prior-year period |
| Net loss | $3.35 million for six months; $1.74 million for the quarter |
Margins are not meaningful because the company had no revenue. No specific cash-runway estimate is provided.
Results and changes versus prior periods
- For the six months, R&D expense declined 27% to $1.43 million, while G&A rose 6% to $1.97 million. Net loss narrowed to $3.35 million from $3.80 million.
- For the quarter, R&D declined 25% to $712,193 and G&A increased 20% to $1.05 million. Net loss was $1.74 million versus $1.81 million.
- Management attributed lower R&D mainly to timing of prior-year drug manufacturing, completed or deferred preclinical work, reduced patent spending, and lower personnel costs. Higher G&A reflected professional fees, investor outreach, insurance, office costs, and personnel.
- Financing provided $6.61 million net cash in the six-month period, primarily from an August 2019 public offering. Operating cash use increased year over year, in part reflecting a $993,766 reduction in accounts payable and accrued liabilities.
Outlook, trials, risks, and unusual items
- Funding and going concern: Management stated that additional funding will be needed for trials and general operations and that substantial doubt exists about the company’s ability to continue as a going concern within one year from the filing date. Management was pursuing equity financing and/or strategic partnerships, with no assurance of success; programs could be adjusted, delayed, reduced, or discontinued.
- Clinical program: The filing describes two ongoing Phase 2 studies across newly diagnosed, recurrent, and adjuvant GBM settings. At the stated data cutoffs, the SYSUCC study had enrolled 23 of 30 planned patients; interim median PFS was 9.9 months among 22 evaluable patients and 10.4 months among 18 initially treated at the selected dose. The MD Anderson recurrent arm had enrolled 62 patients; reported median overall survival was 7.5 months among 60 patients and 10.6 months among 25 initially treated at 30 mg/m²/day. These are interim, single-arm results compared with historical benchmarks, not head-to-head evidence. The adjuvant arm had enrolled 5 of up to 24 patients.
- Management said August’s financing was expected to support full enrollment in all three patient groups by the fourth quarter of calendar 2020. This is an enrollment expectation, not a regulatory or commercial forecast.
- VAL-083’s reported principal dose-limiting toxicity is myelosuppression, particularly low platelet counts. Four subjects in the newly diagnosed group and eleven in the recurrent group had experienced possibly drug-related serious adverse events at the cited cutoffs; none were reported in the adjuvant group.
- Capital and dilution: The August offering generated $6.58 million net and included common shares and warrants. At December 31, 9.96 million warrants were outstanding; the filing also reports preferred stock convertible into common shares and options, including 799,199 options subject to stockholder approval of a plan share increase. Common shares outstanding were 11,412,338 as of February 12, 2020.
- Nasdaq listing: Nasdaq notified the company on September 26, 2019 of noncompliance with the $1.00 minimum bid-price requirement, with a deadline of March 24, 2020 to regain compliance. The filing warns that delisting could impair liquidity and access to capital.
- Controls and contingencies: Management concluded disclosure controls were not effective due to a material weakness previously reported in the 2019 Form 10-K; no material control changes were reported for the quarter. The company reported no legal proceedings and no off-balance-sheet arrangements. No subsequent events requiring disclosure were identified other than shares and warrants issued for services.
Most important facts to verify
- Confirm the intended issuer and reporting period: the provided filing is DelMar’s, not Tuhura Biosciences’, and covers the quarter ended December 31, 2019.
- Assess whether financing after the reporting date was obtained and whether the going-concern uncertainty was resolved.
- Review full trial protocols, patient-level context, safety data, and updated results; the cited efficacy figures are interim and use historical comparisons.
- Check subsequent share and warrant counts, potential dilution, and the outcome of the Nasdaq bid-price compliance process.
- Review the 2019 Form 10-K for details of the material weakness and any remediation progress.